Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Postive Metastatic Breast Cancer (MBC)
Document Type
Presentation
Publication Date
12-6-2022
Keywords
oregon; portland; chiles
Clinical Institute
Cancer
Clinical Institute
Women & Children
Department
Oncology
Recommended Citation
Geyer, CE and Page, DB, "Safety Analyses of NRG BR004: A Randomized, Double-blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-line HER2-Postive Metastatic Breast Cancer (MBC)" (2022). Articles, Abstracts, and Reports. 6997.
https://digitalcommons.providence.org/publications/6997
Comments
Geyer CE, Tang G, Rastogi P, Valero V, Chia SK, Cobain EF, Obeid E, Page DB, Poklepovic AS, Irvin WJ, Brufsky AM, Wapnir IL, Suga JM, Mamounas E, Wolmark N. SABCS Annual Meeting; December 6-10; San Antonio, TX. 2022: OT2-16-05.